Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. [electronic resource]
Producer: 20100816Description: 319-31 p. digitalISSN:- 1873-5576
- Animals
- Antigens, Nuclear -- metabolism
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Blotting, Western
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cyclin-Dependent Kinase Inhibitor p21 -- metabolism
- DNA-Binding Proteins -- metabolism
- Deoxycytidine -- analogs & derivatives
- Dose-Response Relationship, Drug
- Enzyme Inhibitors -- pharmacology
- Female
- Humans
- Immunoprecipitation
- Indoles -- pharmacology
- Ku Autoantigen
- Mice
- Mice, Inbred ICR
- Mice, SCID
- Pancreatic Neoplasms -- drug therapy
- Protein Binding
- Proto-Oncogene Proteins c-mdm2 -- antagonists & inhibitors
- RNA Interference
- Sirtuin 1 -- metabolism
- Spiro Compounds -- pharmacology
- Surface Plasmon Resonance
- Time Factors
- Transfection
- Tumor Burden
- Tumor Suppressor Protein p53 -- genetics
- Xenograft Model Antitumor Assays
- bcl-2-Associated X Protein -- metabolism
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.